Klick Health taps former Razorfish exec for new chief brand strategy officer role

Klick Health chief brand strategy officer Carl Turner
Klick Health continues to add personnel. The latest is Carl Turner, the agency's first-ever chief brand strategy officer. (Alpha Stock Images)

Klick Health has hired veteran brand strategist Carl Turner for a newly created role aimed at elevating the strategy function at the agency. As Klick’s first chief brand strategy officer, Turner will helm the agency’s existing brand strategy group and work to grow and evolve it.

“As we continue to evolve the marriage of activation, brand strategy, creative and medical it was something we really wanted to lean into," Glenn Zujew, Klick’s executive vice president of creative and medical, said. "The role of a chief was born out of knowing we needed this to be a prominent role in the organization and we wanted to elevate the craft, but it also became obvious with the level that Carl was at that this was a perfect fit.”

RELATED: Klick goes on creative director hiring spree thanks to new business

Klick chose Turner after more than eight months of searching, Zujew said. He was most recently at Publicis Health’s Razorfish as managing partner and chief strategy officer and before that worked at Saatchi & Saatchi Wellness, Publicis Lifebrands, JWT, Commonground and Palio in a variety of brand strategy roles.

“All forms of strategy are really valued by our clients now and it’s about, 'how do you integrate those forms of strategy in ways that bring about new value for the client?' Our clients are clamoring for strategy,” Turner said.

He’s looking forward to working at the growing and entrepreneurial agency, which recorded double-digit growth last year and added new business in therapeutic areas including migraine, ADHD, women’s and men’s health and oncology.

RELATED: Klick Health spills its secrets in new pharma marketing playbook

“One of the great advantages of working at Klick is the cross fertilization that happens between all the disciplines,” Turner said, adding that, “The ability to work in an entrepreneurial fashion and influence each other with new ways of thinking is where the excitement comes from.”

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.